Company profiles
ARJIL Pharmaceuticals LLC, founded in 2014, is a development stage specialty pharmaceutical company which focused on advancing and commercializing innovative medical products. Since its inception, Arjil are committed to the ongoing discovery, development and delivery of botanical basis medicines for elderly globally.
The contributed capital of Arjil in 2020 is up to 108.9 M.
Yeh B, Wu MD.
Chairman of the board
New York University Bellevue Hospital , NY
Setup anesthesia and pain clinic, NJ
Investment in Arch Venture Fund, Chicago
Zeitech Corp Chairman, NJ
TBS Pharmaceutical Company Board of Directors,NJ
Barjil Investment Group Chairman, NJ
Our Team
Biomedical Technology and Device
Research Laboratories, ITRI
Natural product isolation
NTOU, Master
Hui-Ju Liang
Product Manager
Dr. Li-Ling Chao
Chief Financial Officer
Postdoc. National Changhua University of Education
Green Flatek, INC. manager
Tunghai University; Adjunct Assistant Professor
Postdoc. National Chung Hsing University
PhD, Biotechnology, NCHU
Dr. Ming-Kun Chen
Manager
Richard Wu, MD
medical adviser
Dr. Jane SC Tsai
Honorary Consultant U.S.A.
Emergency Care and Thoracic Specialty
Columbia University
SVP(Senior Vice President)
International Affairs,
YFY Biotech Management Company
Senior Advisor,
Former Deputy General Director and COO(Chief Operating Officer),
CTO(Chief Technology Officer),
ITRI
Roche Former Director,
Our services
We are committed to developing medicines for unmet medical needs and improving quality life products, including bioactive botanical cosmetic ingredients, healthy foods derived from botanical drugs, and anti-aging products for improving and extending quality of life for elderly people.
Our strength
With the QMS (Quality Management System) having been established on our organization infrastructure along the IND process, we have been holistically approaching and accelerating our drug R&D in data driven & risk managed (assessed) manners, and consistently moving toward a successful track in a predictable way.